Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Blazesbon Jul 03, 2020 5:55pm
362 Views
Post# 31222580

RE:RE:RE:RE:RE:RE:RE:July 10

RE:RE:RE:RE:RE:RE:RE:July 10
MUGMODs wrote: Every indication from the company says they are going into partnering mode.
They have partinering in over 50 countries to date - small countries.
Cashed up to buy time.
Opened the data room and allow companies to review the data - has been a busy place.
Paying for partnering studies in different (larger) regions/countires.

They have the best NSAID on the market - one that stands alone on CV safety and GI safety.

It's not about wishing - it's a process that will take some time.  You certainly can say that you FEEL there's little partnering interest ... but ... I'd still like to know why you believe that.

I would absolutely bet against that feeling.

Antibe made a DEAL.  They dealt 1/4 of the company, 100,000,000 shares of the company at .40 cents a share to raise 28 million dollars. Got that? 

It is the only deal they have made. Got that?

Then they sold personal holdings at prices above .70 cents per share BEFORE announcing the DEAL.  Got that?

Results from the last test of drug '46' on 360 patients was compromised--called 'significant' in the press release--by two weeks of post test acetaminophin administered to those patients which supposedly is a standard protocol of such tests.  The inclusion of the word 'significant' in the company's announcement has suppressed the share price. Got that?

Recessions and bear markets influence behaviour from the macro scale to the micro scale.

On the macro side central banks worldwide are digitally printing trillions of dollars which they exchange with investment banks for 3 month low interest bearing notes.  Those banks make available that newly created cash to business as a sort of 'grease' to keep the wheels of the global economy moving.  Otherwise things grind to a halt.

On the micro side companies adjust to the new economic conditions. A premium is placed upon survival.  Growth is not a top priority because the customers which fuel growth are all at home unemployed, quarantined or otherwise employed but battening down the hatches.

Antibe's DEAL with the underwriting syndicate reflects their understanding of these new realities. They took the money to stay in business...a prudent decision.

So too must the behaviour of management's front running before announcing the deal be viewed.  They lined their pockets.  It was cold blooded.  Unethical as hell.  But their bank accounts are flush.  Their kids can go to college if they can find one that is open.

Your continued optimism that partnerships, takeovers and such kind of deals are imminent reflect an assumption now outmoded and obsolete based as it is on economic conditions that no longer obtain.  Got that?

It is your own feelings that are getting in the way of understanding where things now stand with Antibe.

Good luck.     
  

 

 
Bullboard Posts